검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Opdivo |
Overview Company | Merck | Bristol Myers Squibb |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | Nasopharyngeal Cancer |
Overview Indication | Multiple solid tumors | Colorectal Cancer |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | APPROVED | RECRUITING |
MoA Mechanism | PD-1 blockade → T-cell reinvigoration | binds to the PD-1 receptor |
MoA Biomarker | PD-L1, MSI-H, TMB | PD-1 with slow dissociation and preferential binding in TME-mimicking low |
PK/PD Half-life | 3 h | — |
PK/PD Species | Mouse, Human | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro | Mouse |
PK/PD Experiment | PD | PD |
Toxicology Species | Macaque, Mouse, Rat, Human | Mouse |
Toxicology Animal (cat.) | — | Mouse |
Toxicology Major finding | Immune-related AEs | Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4.. Dual Opdivo plus Yervoy immunotherapy, targeting the immune checkpoints PD1 and CTLA-4, is successful in clinical use. However, it is associated with a high incidence of adverse events, and its therapeutic efficacy needs improving. In this study, p… |
Toxicology CRS | N/A | — |
Clinical Primary efficacy | ORR 38% | ORR 100% |
Clinical ORR | 38% | 100% |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT03267498 |
Clinical Data Tier / Score | S · 80 | C · 64 |
Clinical Program phase | APPROVED | PHASE_2 |
Clinical Dose / schedule | q3w or q6w | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 7일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Opdivo |
Overview Company | Merck | Bristol Myers Squibb |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | Nasopharyngeal Cancer |
Overview Indication | Multiple solid tumors | Colorectal Cancer |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | APPROVED | RECRUITING |
MoA Mechanism | PD-1 blockade → T-cell reinvigoration | binds to the PD-1 receptor |
MoA Biomarker | PD-L1, MSI-H, TMB | PD-1 with slow dissociation and preferential binding in TME-mimicking low |
PK/PD Half-life | 3 h | — |
PK/PD Species | Mouse, Human | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro | Mouse |
PK/PD Experiment | PD | PD |
Toxicology Species | Macaque, Mouse, Rat, Human | Mouse |
Toxicology Animal (cat.) | — | Mouse |
Toxicology Major finding | Immune-related AEs | Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4.. Dual Opdivo plus Yervoy immunotherapy, targeting the immune checkpoints PD1 and CTLA-4, is successful in clinical use. However, it is associated with a high incidence of adverse events, and its therapeutic efficacy needs improving. In this study, p… |
Toxicology CRS | N/A | — |
Clinical Primary efficacy | ORR 38% | ORR 100% |
Clinical ORR | 38% | 100% |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT03267498 |
Clinical Data Tier / Score | S · 80 | C · 64 |
Clinical Program phase | APPROVED | PHASE_2 |
Clinical Dose / schedule | q3w or q6w | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 7일 (6일 전) |
추천 비교
추천 비교